IXA is a network, servicedesk and liaison, all in one.
We offer researchers the expertise of grant advisers, business developers and legal experts to help determine a valorisation/ impact strategy. We assist in setting up collaborations with third parties and/or starting new ventures, while managing intellectual property and other legal and financial support. For researchers to develop their skills on valorisation and entrepreneurship, IXA organises workshops, courses and masterclasses on a regular basis. Go to For researchers for more information or have a look at our Workshops & Events page.
For companies, non-profits, governments, health care and educational institutions, etc., we provide a gateway to research expertise, high-tech facilities and research infrastructure, contract research, collaboration and investment opportunities. Go to For companies/non-profits to find out more.
Next to offering a wide range of services, we closely cooperate with other parties within the Amsterdam innovation landscape. When opportunities arise, IXA takes the lead in developing programs and activities to further stimulate economic activity and entrepreneurship in research and education.
Teachers from the department of medical informatics of Amsterdam UMC have developed an online platform to gather and visualize structured curriculum information, called act-E. Education managers, teachers and students use this platform to gain insights regarding their curricula that could never be viewed as easily before. These insights help them to have an informed conversation […]News
VU alumni International Business Administration Michael Musandu and Ugnius Rimsa founded Lalaland in 2019. The startup generates and hyper personalizes full human body models from head to toe by using AI. As a result, models are available in different ethnicities, sizes and ages, allowing customers to always recognize themselves in the clothing of their choice. […]News
Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. Now, a monoclonal antibody, named BION-1301 (anti-APRIL), is being developed to treat patients with IgA nephropathy. BION-1301 is a potential disease-modifying approach to prevent the formation of […]News